Skip to main content
Premium Trial:

Request an Annual Quote

Bayer CropScience Earmarks Almost $1B in US Investments for 2013 to 2016

NEW YORK (GenomeWeb) – Bayer CropScience today said that it is investing almost $1 billion in capital expenditures in the US between 2013 and 2016 to build up its R&D capabilities and expand its supply of crop protection brands.

The funding is part of a global investment program that Bayer CropScience began last year with total capital expenditures of €2.4 billion ($3.3 billion) between 2013 and 2016.

As part of the new US investments, Bayer CropScience's new integrated R&D site in West Sacramento, Calif., was inaugurated today. The $80 million facility, which will be the headquarters for Bayer CropScience's biologics business, includes a 100,000-square-foot building, a 35,000-square-foot pilot plant to support R&D of biological crop protection products, a 30,000-square-foot vegetable seeds research building, and a 2,000-square-foot greenhouse. The facility has the capacity to house up to 300 employees.

The company said that it has also invested $17 million to expand its Memphis R&D site, bringing the total greenhouse capacity at the facility to 76,000 square feet. Researchers there support Bayer CropScience's global cotton and soybean seed businesses by using molecular breeding and other technologies.

Other investments are targeted at the company's North American and global seeds headquarters in Research Triangle Park, NC; the construction of the Development North America facility dedicated to crop protection and environmental science research; renovations to Bayer CropScience's North American headquarters, scheduled to be completed in 2015; the Cotton Research and Development Laboratory in Lubbock, Texas; and other facilities.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.